In Brief
Refine Search
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Biotechnology
The Australian Therapeutic Goods Administration (TGA) said today that it has commenced evaluation of an application from the local subsidiary of US mRNA vaccines specialist Moderna to transition its Spikevax (COVID-19 Vaccine, mRNA), to full registration for the immuniz0ation of individuals six years and over, and as a booster dose for individuals aged 12 years and older. 20 January 2023
Biotechnology
Chinese biotech company BeiGene has announced that the US Food and Drug Administration (FDA) has approved Brukinsa (zanubrutinib) for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). 20 January 2023
Biotechnology
Positive Phase III results for Shanghai’s Junshi Biosciences will lift the company’s prospects in the competitive market for lung cancer therapies. 20 January 2023
Biotechnology
Patient groups have expressed disappointment that USA-based drugmaker Eli Lilly has not been granted an Accelerated Approval for its Alzheimer’s disease candidate, donanemab. 20 January 2023
Biotechnology
Cambridge, USA-based genome editing company Editas Medicine has entered into a definitive agreement with US biotech Shoreline Biosciences (Shoreline) to license Editas Medicine’s proprietary SLEEK (SeLection by Essential-gene Exon Knock-in) and AsCas12a gene editing technologies and acquire Editas Medicine’s pre-clinical gene edited induced pluripotent stem cell (iPSC) derived natural killer cell (iNK) programs and related manufacturing technologies. 20 January 2023
Biotechnology
On Thursday, the US Food and Drug Administration (FDA) granted accelerated approval for Seagen’s Tukysa (tucatinib) in combination with trastuzumab for RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. 20 January 2023
Biotechnology
After a difficult year for investment, look for the biotech industry to engage in creative dealmaking in the market, leading to faster innovation in the lab, Protagonist Therapeutics CEO Dinesh Patel writes in Bio.News. 20 January 2023
Pharmaceutical
Leading Indian drugmaker Sun Pharmaceutical Industries today announced a definitive agreement under which Sun Pharma will acquire all outstanding shares of US firm Concert Pharmaceuticals, with the news pushing the latter's shares up more than 20% to $8.30. 19 January 2023
Pharmaceutical
Massachusetts, USA-based psychoactive medicine specialist Sensorium Therapeutics has appointed Jeffrey Brown as chief scientific officer. 19 January 2023
Biotechnology
Following on from European Commission (EC) approvals in November, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorizations for Brukinsa (zanubrutinib) in Great Britain. 19 January 2023
Biotechnology
The UK health technology assessor, the National Institute for Health and Care Excellence (NICE) has issued a Final Evaluation Document recommending Translarna (ataluren) for reimbursement and use across the National Health Service (NHS) in England and Wales in the treatment of Duchenne muscular dystrophy (DMD). 19 January 2023
Biotechnology
RNAi specialist Alnylam Therapeutics’ Amvuttra (vutrisiran) has been recommended for use on the National Health Service (NHS) in England as an option for treating hereditary transthyretin-related (ATTRv) amyloidosis. 19 January 2023
Biotechnology
The pivotal Phase III IMbrave050 study, which investigated PD-L1 inhibitor Tecentriq (atezolizumab) plus anti-VEGF antibody Avastin (bevacizumab) in people with early-stage hepatocellular carcinoma or HCC at high risk of recurrence following surgery, met primary endpoint of recurrence-free survival at the prespecified interim analysis, according to Swiss pharma giant Roche. 19 January 2023
Pharmaceutical
An investigational HIV vaccine regimen tested among men who have sex with men (MSM) and transgender people was safe but did not provide protection against HIV acquisition compared to placebo, an independent data and safety monitoring board (DSMB) has determined. No safety issues with the regimen were identified, but it is another blow for hopes of a vaccine against the virus. 19 January 2023
Biotechnology
Sino-American biotech BeiGene saw its shares rise 3.5% to 160.51 renminbi, after it announced that the National Reimbursement Drug List (NRDL) released by China’s National Healthcare Security Administration (NHSA) has been updated to include four new indications for its PD-1 inhibitor tislelizumab. 19 January 2023
Biotechnology
Neurodegenerative diseases specialist APRINOIA Therapeutics has announced a merger with Ross Acquisition Corp II, a special purpose acquisition company (SPAC) founded by former US Secretary of Commerce Wilbur Ross. 18 January 2023
Biotechnology
Negotiations with the China National Healthcare Security Administration (NHSA) have borne fruit for Hutchmed and its product Orpathys (savolitinib). 18 January 2023
Biotechnology
EVOQ Therapeutics and fellow USA-based Amgen today announced they are advancing their ongoing license and collaboration agreement for the discovery and development of novel therapeutics including the receipt of a milestone payment and expansion of the scope of collaboration to include a total of three indications in autoimmune disorders. 18 January 2023
Biotechnology
SFJ Pharmaceuticals is claiming victory in its legal dispute with cardiopulmonary diseases focussed US firm PhaseBio Pharmaceuticals regarding a blood thinner reversal agent, announcing the closing of the sale and transfer of assets related to bentracimab from PhaseBio to SFJ. 18 January 2023
Pharmaceutical
There is no shortage of criticism currently being directed at the UK government from the public sector, especially where healthcare is concerned ... 18 January 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze